Rare subcutaneous metastases of papillary thyroid carcinoma revealed by 18 F-FDG PET/CT.

Semin Nucl MedJul 30, 2026 (epub)
Case ReportOncology (Medical)Endocrinology

Semra Demirtaş Şenlik, Barış Yılmaztekin, Ayşegül Erol et al.

✦ AI-curated · Sources linked

Case in brief

A 76-year-old woman with a history of papillary thyroid carcinoma (PTC) underwent multiple treatments, including thyroidectomy and radioactive iodine therapy. Despite undetectable thyroglobulin levels, she experienced two consecutive increases in thyroglobulin, leading to an 18 F-FDG PET/CT scan that revealed multiple subcutaneous lesions. A biopsy confirmed these lesions as metastatic PTC with a tall-cell component.

What made this case unusual

The case highlights the presence of subcutaneous metastases in PTC, which is an atypical manifestation not commonly associated with this type of cancer.

Diagnostic / clinical pearl

Clinicians should consider the possibility of subcutaneous metastases in patients with papillary thyroid carcinoma, even when thyroglobulin levels are low.

Why it matters

This case underscores the importance of advanced imaging techniques like 18 F-FDG PET/CT in detecting atypical metastatic sites in thyroid cancer patients.

Source

PubMed · PMID 42532757

Published in Semin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.